More than just a company
Biametrics was founded in 2010 by Dr. Florian Pröll and Dr. Günther Proll as a spin-off of the University of Tübingen. What started as a crazy idea has grown into a company with more than 10 staff members in 2016. We consider Biametrics as a family with our products being our children. And due to our passion about science and our enthusiasm for working in the laboratory, our kids are infused with all the tech-savvy good ideas we found were missing on other devices we had to work with during our education. Our first kid (the b-screen) saw the light of day in 2015 and its small sibling (the b-portable) will follow in 2017. Even if we are providing real physical products, we consider ourselves not as classical salesmen, but rather as „problem solvers“, with the philosophy: „Your challenges are our challenges“. We want to provide you with the solution you really need, instead of just selling you one of our products.
Oh and beside that, we combine all the classical German virtues like punctuality, quality, and humour.
Dr. Florian Pröll (CEO)
Dr. Florian Pröll (* 1978) studied Chemistry at the University of Tübingen, Germany, with a specialisation in Analytical Chemistry and Optical Spectroscopy. In 2010, he received his PhD at the University of Tübingen in the group of Prof. Dr. Günter Gauglitz for his work on imaging Reflectometric Interference Spectroscopy (iRIfS). This biosensor system for highly-parallelised analysis of label-free biomolecular interactions was the basis for the development of the new SCORE technology. He has published 15 original papers and book chapters.
In 2010, he founded Biametrics GmbH together with Dr. Günther Proll.
Biametrics ist certified according to ISO 9001:2008 and 14001:2004.
Dr. Günther Proll (CEO)
Dr. Günther Proll (* 1974) studied Technical Biology at the University of Stuttgart, Germany with a specialisation in Physical Chemistry and Optical Spectroscopy. In 2005, he received his PhD at the University of Tübingen in the group of Prof. Dr. Günter Gauglitz for his work on a biosensor system for automated ultra-sensitive multi-analyte immunoassays using total internal reflection fluorescence (TIRF). Since 2009, he is a member of the board of the working „Chemo- and Biosensors“ within the Analytical Chemistry division of the Gesellschaft Deutscher Chemiker (GDCh). He has published 30 original articles and 4 book chapters.
In 2010, he founded Biametrics GmbH together with Dr. Florian Pröll.
Research & Development
Dr. Peter Fechner
Marketing & Sales
Dr. Julia Schütte
Dr. Michael Ruppert
Dr. Alexander Sinclair
Praktikumsmöglichkeiten im Bereich Hardwareentwicklung
Für Studierende und Auszubildende aus den Bereichen Ingenieurwissenschaften, Maschinenbau, Mechatronik, Medizintechnik, Physik oder (Bio-)Informatik bietet Biamterics die Möglichkeit, einen Einblick in den Berufsalltag von Entwicklungsingenieuren in einem innovativen Unternehmen zu erhalten. Bewerben sie sich jetzt auf ein Praktikum (mindestens 12 Wochen) zu aktuellen Themen aus dem Bereich Hardwareentwicklung.
Praktikumsmöglichkeiten im Bereich Biosensorentwicklung
Für Studierende und Auszubildende im Bereich Naturwissenschaften, Life-Sciences, Biotechnologie oder Medizintechnik bietet Biamterics die Möglichkeit, einen Einblick in die Forschungs- und Laborarbeit in einem innovativen Unternehmen zu erhalten. Bewerben sie sich jetzt auf ein Praktikum (mindestens 8 Wochen) zu aktuellen Themen aus dem Bereich Biosensorentwicklung.
Looking for a job? Send us your unsolicited application!
The Biamertics technology allows us to analyse our arrays in high throughput and, at the same time, reveal details of the binding events. We expect that the b-screen system will facilitate our efforts to develop protein modulators with therapeutic potential as well as protein labels for super-resolution microscopy. We are looking forward to continue our close collaboration with Biametrics to create a technology platform that allows the combined synthesis & interaction analysis of modified peptides in highest throughput.
Asst. Prof. Dr. Hans Michael Maric, Center for Biopharmaceuticals, Department of Drug Design and Pharmacology
University of Copenhagen